Other: fed circuit mandate | Jul 25, 2022 | PAPER | BOARD |
Other: other court decision | Jul 25, 2022 | PAPER | BOARD |
Trial Certificate Checklist | Jul 25, 2022 | PAPER | BOARD |
Patent Owner's Notice of Appeal | Jun 2, 2020 | PAPER | PATENT OWNER |
Judgment - Final Written Decision - Determining All Challenged Claims Unpatentable | May 28, 2020 | PAPER | BOARD |
Petitioner's Updated Mandatory Notices | Mar 27, 2020 | PAPER | PETITIONER |
Hearing Transcript | Mar 18, 2020 | PAPER | BOARD |
Patent Owner's Updated Exhibit List | Mar 3, 2020 | PAPER | PATENT OWNER |
Patent Owner's Demonstratives | Mar 3, 2020 | EXHIBIT | PATENT OWNER |
Petitioner's Updated Exhibit List | Mar 3, 2020 | PAPER | PETITIONER |
Petitioner's Demonstratives | Mar 3, 2020 | EXHIBIT | PETITIONER |
ORDER
Oral Hearing
37 C.F.R. 42.70 | Jan 27, 2020 | PAPER | BOARD |
Table A1 Pairings of Targets and Drugs | Jan 23, 2020 | EXHIBIT | PATENT OWNER |
Patent Owner's Sur-Reply | Jan 23, 2020 | PAPER | PATENT OWNER |
Nicholson, Modulation of Epidermal Growth Factor Receptor in Endocrine Resistant, Oestrogen Receptor Positive Breast Cancer | Jan 23, 2020 | EXHIBIT | PATENT OWNER |
Moulder, et al. Epidermal Growth Factor Receptor (HER1) Tyrosine Kinase Inhibitor ZD1839 (Iressa) Inhibits HER2/neu (erbB2) overexpressing Breast Cancer Cells in Vitro and In Vivo | Jan 23, 2020 | EXHIBIT | PATENT OWNER |
Transcript of the Deposition of Paul T. Spellman, Volume II, January 15, 2020 | Jan 23, 2020 | EXHIBIT | PATENT OWNER |
Patent Owner's Request for Oral Argument | Jan 21, 2020 | PAPER | PATENT OWNER |
PETITIONER'S REQUEST FOR ORAL ARGUMENT | Jan 21, 2020 | PAPER | PETITIONER |
Patent Owner's Updated Mandatory Notices | Jan 14, 2020 | PAPER | PATENT OWNER |
Decision - Granting Patent Owner's Motions for Pro Hac Vice Admission of Jonathan Singer - 37 CFR 42.10 | Jan 10, 2020 | PAPER | BOARD |
Order - Modifying the Scheduling Order - 37 CFR 42.5(c) | Jan 10, 2020 | PAPER | BOARD |
Ex. 3004 | Jan 10, 2020 | EXHIBIT | BOARD |
Patent Owner's Notice of Deposition of Paul T. Spellman, Ph.D | Dec 30, 2019 | PAPER | PATENT OWNER |
PETITIONER'S REPLY TO PATENT OWNER'S RESPONSE | Dec 12, 2019 | PAPER | PETITIONER |
Chen, 9 The Oncologist 27 (2004) | Dec 12, 2019 | EXHIBIT | PETITIONER |
Deposition Transcript of Joyce A. O'Shaughnessy, M.D., Volume 1 of 2 | Dec 12, 2019 | EXHIBIT | PETITIONER |
Deposition Transcript of Joyce A. O'Shaughnessy, M.D., Volume 2 of 2 | Dec 12, 2019 | EXHIBIT | PETITIONER |
Reply Declaration of Paul T. Spellman, Ph.D. | Dec 12, 2019 | EXHIBIT | PETITIONER |
Mori et al., 17 Intl J. Oncology 33 (2000) | Dec 12, 2019 | EXHIBIT | PETITIONER |
HUGO Gene Nomenclature Committee Symbol Report | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Robert J. Penny | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Matthew McGinniss | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Ryan Bender | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Traci Pawlowski | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Arlet Alarcon | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Alan Wright | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. David Loesch | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Marina Bibikova | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Joanne Yeakley | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Eugene Chudin | Dec 12, 2019 | EXHIBIT | PETITIONER |
NFCR profile for Dr. Daniel A. Haber | Dec 12, 2019 | EXHIBIT | PETITIONER |
Cold Spring Harbor Laboratory profile for Dr. Raffaella Sordella | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Eunice Kwak | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Jeffrey Settleman | Dec 12, 2019 | EXHIBIT | PETITIONER |
LinkedIn profile for Dr. Nadia Godin-Heymann | Dec 12, 2019 | EXHIBIT | PETITIONER |
NFCR profile for Dr. Brian Leyland-Jones | Dec 12, 2019 | EXHIBIT | PETITIONER |
U.S. Provisional Patent Application No. 60/747,645 | Dec 12, 2019 | EXHIBIT | PETITIONER |
U.S. Patent Application Publication No. 2008-0014146 | Dec 12, 2019 | EXHIBIT | PETITIONER |
File History Excerpt for U.S. Patent Application No. 11/750,721 | Dec 12, 2019 | EXHIBIT | PETITIONER |
U.S. Patent No. 8,700,335 | Dec 12, 2019 | EXHIBIT | PETITIONER |
Kouwaki et al. 4 Clinical Cancer Res. 2999 (1998) | Dec 12, 2019 | EXHIBIT | PETITIONER |
Clinical Trial Ref. No. NCT00065533 | Dec 12, 2019 | EXHIBIT | PETITIONER |
Doxorubicin Hydrochloride for Injection Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
TAXOL Injection Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
Etienne et al., 12 J. Clinical Oncology 2248 (1994) | Dec 12, 2019 | EXHIBIT | PETITIONER |
Longley et al., 3 Nature Reviews Cancer 330 (2003) | Dec 12, 2019 | EXHIBIT | PETITIONER |
Fluorouracil Injection Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
Clinical Trial Ref. No. NCT00006121 | Dec 12, 2019 | EXHIBIT | PETITIONER |
Clinical Trial Ref. No. NCT00066339 | Dec 12, 2019 | EXHIBIT | PETITIONER |
Clinical Trial Ref. No. NCT00113373 | Dec 12, 2019 | EXHIBIT | PETITIONER |
Clinical Trial Ref. No. NCT00305838 | Dec 12, 2019 | EXHIBIT | PETITIONER |
Clinical Trial Ref. No. NCT01051596 | Dec 12, 2019 | EXHIBIT | PETITIONER |
National Women's Health Network | Dec 12, 2019 | EXHIBIT | PETITIONER |
Approval Package for STILBESTROL | Dec 12, 2019 | EXHIBIT | PETITIONER |
XEXLODA Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
AROMASIN Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
Fluorouracil Injection Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
GEMZAR Injection Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
FEMARA Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
Paclitaxel Injection Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
HERCEPTIN Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
AVASTIN For Intravenous Use Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
CAMPTOSAR Injection Label | Dec 12, 2019 | EXHIBIT | PETITIONER |
Beumer et al., 156 Breast Cancer Res. Treatment 279 (2016) | Dec 12, 2019 | EXHIBIT | PETITIONER |
Declaration of Jonathan Singer | Dec 5, 2019 | EXHIBIT | PATENT OWNER |
Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Jonathan Singer | Dec 5, 2019 | PAPER | PATENT OWNER |
PANEL CHANGE ORDER
Conduct of the Proceedings
37 C.F.R. ¿¿ 42.5 | Nov 21, 2019 | PAPER | BOARD |
Patent Owner's Updated Mandatory Notices | Oct 18, 2019 | PAPER | PATENT OWNER |
Patent Owner's Updated Power of Attorney | Oct 18, 2019 | PAPER | PATENT OWNER |
Granting Patent Owner's Motions for Pro Hac Vice Admission of Corrin Drakulich | Oct 15, 2019 | PAPER | BOARD |
Granting Patent Owner's Motions for Pro Hac Vice Admission of Christina Brown-Marshall | Oct 15, 2019 | PAPER | BOARD |
Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Corrin Drakulich | Oct 4, 2019 | PAPER | PATENT OWNER |
Declaration of Corrin Drakulich | Oct 4, 2019 | EXHIBIT | PATENT OWNER |
Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Christina Brown-Marshall | Oct 3, 2019 | PAPER | PATENT OWNER |
Declaration of Christina Brown-Marshall | Oct 3, 2019 | EXHIBIT | PATENT OWNER |
Petitioner's Notice of Deposition of Joyce A. O'Shaughnessy, M.D. | Sep 27, 2019 | PAPER | PETITIONER |
Hanahan, et al., ¿¿¿The Hallmarks of Cancer,¿¿¿ Cell, Vol. 100, 57-70, January 7, 2000 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Sorlie, et al., ¿¿¿Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Sets,¿¿¿ PNAS Vol. 100, No. 14, July 8, 2003, pp. 8418-8423. | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
The Cancer Genome Atlas Research Network et al., ¿¿¿The Cancer Genome Atlas Pan-Cancer Analysis Project,¿¿¿ Nature Genetics, Vol. 45, No. 10, October 2013, pp. 1113-1120 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Corless et al., ¿¿¿Tackling Formalin-Fixed, Paraffin-Embedded Tumor Tissue with Next-Generation Sequencing,¿¿¿ Cancer Discovery, January 12, 2012, pp. 23-24 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Gleevec¿¿ Label, downloaded from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021335 on August 19, 2019, 22 pages | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Expert Declaration of Joyce O¿¿¿Shaughnessy, M.D. | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Hanahan, et al., ¿¿¿The Hallmarks of Cancer,¿¿¿ Cell, Vol. 100, 57-70, January 7, 2000 | Sep 19, 2019 | PAPER | PATENT OWNER |
National Comprehensive Cancer Network, ¿¿¿Colon Cancer Version 1.2017 Clinical Practice Guidelines in Oncology¿¿¿, Journal of the National Comprehensive Cancer Network, Vol. 15, No. 3, March 2017, pp. 370-398 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Lawrence et al., ¿¿¿Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations,¿¿¿ Journal of Clinical Oncology, May 15, 2001, pp. 2754-2763 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Gleevec¿¿ FDA 2001 Approval Letter downloaded from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021335 on August 19, 2019, 3 pages | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Leslie A. Pray, ¿¿¿Gleevec¿¿: The Breakthrough in Cancer Treatment,¿¿¿ Nature Education, Vol. 1, 2008, 4 pages | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Gleevec¿¿ FDA 2002 Approval Letter downloaded from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021335 on August 19, 2019, 4 pages | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Avastin¿¿, Highlights of Prescribing Information downloaded from the internet at https://www.gene.com/download/pdf/avastin_prescribing.pdf on August 15, 2019, 39 pages | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Shen et al., ¿¿¿Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing among Patients with Newly Diagnosed Metastatic Lung Cancer,¿¿¿ Clinical Lung Cancer, Vol. 18, No. 4, July 2017, pp. e233-e241 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Lynch et al., ¿¿¿Activating mutation in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,¿¿¿ NEJM, Vol. 350, May 20, 2004, Abstract | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Paez et al., ¿¿¿EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy,¿¿¿ Science, Vol. 304, June 4, 2004, pp. 1497-1500 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Pao et al., ¿¿¿EGF receptor gene mutations are common in lung cancers from ¿¿¿never smokers¿¿¿ and correlate with sensitivity of tumors to gefitinib (Iressa) and erlotinib (Tarceva),¿¿¿ PNAS, Vol. 101, No. 36, September 7, 2004, pp. 13306-13311 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Tanner et. al, ¿¿¿Amplification of HER-2 in Gastric Carcinoma,¿¿¿ Annals of Oncology, Vol. 16, 2005, pp. 273-278 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
National Comprehensive Cancer Network, ¿¿¿Gastric Cancer Clinical Practice Guidelines in Oncology¿¿¿, Journal of the National Comprehensive Cancer Network, Vol. 1, No. 1, January 2003, pp. 27-39 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Flavell, ¿¿¿Keytruda,¿¿¿ Immuno-Oncology News, downloaded from the internet at https://immuno-oncologynews.com/keytruda-pembrolizumab/ on August 15, 2019, 8 pages | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Richard Simon, ¿¿¿Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers,¿¿¿ Journal of Clinical Oncology, Vol. 23, No. 29, October 10, 2005, pp. 7332-7341 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Corless et al., ¿¿¿PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib,¿¿¿ Journal of Clinical Oncology, Vol. 23, No. 23, August 10, 2005, pp. 5357-5364 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Luchtenborg et al., ¿¿¿Mutations ins APC, CTNNB1 and K-Ras Genes and Expression of hMLH1 in Sporadic Colorectal Carcinomas from the Netherlands Cohort Study,¿¿¿ BMC Cancer, December 15, 2005 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Rodriguez-Viciana et al., ¿¿¿Cancer Targets in the Ras Pathway,¿¿¿ Cold Spring Harbor Laboratory Press (2005), pp. 461-467 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Staker et al., ¿¿¿The Mechanism of Topoisomerase I Poisoning By a Camptothecin Analog,¿¿¿ PNAS, Vol. 99, No. 24, November 26, 2002, pp. 15387-15392 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Cynthia A. Heinlein and Chawnshang Chang, ¿¿¿Androgen Receptor in Prostate Cancer,¿¿¿ Endocrine Reviews, Vol. 25, No. 2, April 2004, p. 276-308 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Kari et. al, ¿¿¿Targeting the Epidermal Growth Factor in Cancer,¿¿¿ Cancer Research, Vol. 63, January 1, 2003, pp. 1-5 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Von Hoff et al., ¿¿¿Frequency of Potential Therapeutic Targets Identified by IHC and DNA Microarray in Tumors From Patients Who Have Progressed on Multiple Therapeutic Agents,¿¿¿ Journal of Clinical Oncology, Vol. 24, No. 18. Suppl.3, June 2006 Abstract | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Fuerst, ¿¿¿Dan Von Hoff¿¿¿s Karnofsky Lecture: Smart Phase I Trials Can Extend Life Beyond ¿¿¿The Last 12 Weeks,¿¿¿¿¿¿ Oncology Times ASCO Meeting Reporter Supplement, August 10, 2010, pp. 21-23 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Haber et al., ¿¿¿Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors,¿¿¿ Cold Spring Harbor Laboratory Press, Vol. LXX, 2005, pp. 419-426 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
DC Allred, ¿¿¿Origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer,¿¿¿ Breast Cancer Research (2004) | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Kanaya et al., ¿¿¿Frequent Hypermethylation of MLH1 Promoter in Normal Endometrium of Patients with Endometrial Cancers,¿¿¿ Oncogene pp. 2352-2360 (2003) | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Mace L. Rothenberg, ¿¿¿Irinotecan (CPT-11): ¿¿¿Recent Developments and Future Directions¿¿¿Colorectal Cancer and Beyond,¿¿¿ The Oncologist, pp. 66-80 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Agoff et al., ¿¿¿Androgen Receptor Expression in Estrogen Receptor-Negative Breast Cancer. Immunohistochemical, Clinical, and Prognostic Associations,¿¿¿ American Journal of Clinical Pathology, Vol. 120, No. 5, November 2003 (Abstract) | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
National Comprehensive Cancer Network, ¿¿¿Breast Cancer Version 4.2017 Clinical Practice Guidelines in Oncology¿¿¿, Journal of the National Comprehensive Cancer Network, Vol. 16, No. 3, March 2018, pp. 310-320 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Zhou et al., ¿¿¿PTEN Mutational Spectra, Expression Levels, and Subcellular Localization in Microsatellite Stable and Unstable Colorectal Cancers,¿¿¿ American Journal of Pathology, Vol. 161, No. 2, August 2002, pp. 439-447 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
B. Ramanath Rao and Berend J. Slotman, ¿¿¿Endocrine Factors in Common Epithelial Ovarian Cancer,¿¿¿ Endocrine Reviews, Vol. 12, Issue 1, February 1, 1991, pp. 14-26 (Abstract) | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Wisniewski et al., ¿¿¿Characterization of Potent Inhibitors of the Bcr-Abl and the c-Kit Receptor Tyrosine Kinases,¿¿¿ Cancer Research, Vol. 62, August 1, 2002, pp. 4244-4255 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Joyce A. O¿¿¿Shaughnessy, ¿¿¿Molecular Signatures Predict Outcomes of Breast Cancer,¿¿¿ The New England Journal of Medicine,¿¿¿ Vol. 355, No. 6, August 10, 2006, pp. 615-617 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Ahmed Ashour Ahmed and James D. Brenton, ¿¿¿Microarrays and Breast Cancer Clinical Studies: Forgetting We Have Not Yet Learnt,¿¿¿ Breast Cancer Research, Vol. 7, No. 3, May 2005, pp. 96-99 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Shi et al., ¿¿¿QA/QC: Challenges and Pitfalls Facing the Microarray Community and Regulatory Agencies, Expert Review of Molecular Diagnostics, Vol. 4, No. 6, (2004) pp. 761-777 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
FoundationOne Sample Report, downloaded from https://www.foundationmedicine.com | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Caris Life Sciences, Sample MiProfile Molecular Intelligence Tumor Report, downloaded from https://www.carismolecularintelligence.com/ | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Adrienne Burke, ¿¿¿Foundation Medicine Personalizing Cancer Drugs,¿¿¿ MIT Technology Review, February 12, 2012, last accessed on September 16, 2019 at https://www.technologyreview.com/s/426987/foundation-medicine-personalizing-cancer-drugs/ | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
¿¿¿About Us: Fulfilling the Promise of Precision Medicine,¿¿¿ downloaded from https://www.carislifesciences.com/about/ on September 16, 2019 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
¿¿¿A Culture Dedicated to Advancing Cancer Care,¿¿¿ downloaded from https://www.foundationmedicine.com/about | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Inokuchi et al., ¿¿¿Abnormality of C-Kit Oncoprotein in Certain Patients With Chronic Myelogenous Leukemia¿¿¿Potential Clinical Significance,¿¿¿ Leukemia 2002, pp. 170-177 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Ohta et al., ¿¿¿Fluorescence in Situ Hybridization Evaluation of c-erbB-2 Gene Amplification and Chromosomal Anomalies in Bladder Cancer,¿¿¿ Clinical Cancer Research, Vol. 7, Issue 9, pp. 2463-2467 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Deposition Transcript of Paul Spellman, Ph.D., Foundation Medicine V. Caris MPI, Inc. July 25, 2019 | Sep 19, 2019 | EXHIBIT | PATENT OWNER |
Patent Owner's Response | Sep 19, 2019 | PAPER | PATENT OWNER |
Petitioner's Updated Mandatory Notices | Sep 18, 2019 | PAPER | PETITIONER |
Decision Granting Petitioner's Motions for Pro Hac Vice Admission of Vinita Ferrera | Sep 18, 2019 | PAPER | BOARD |
Petitioner's Motion For Admission Pro Hac Vice of Vinita Ferrera | Sep 13, 2019 | PAPER | PETITIONER |
Ferrera Declaration | Sep 13, 2019 | EXHIBIT | PETITIONER |
Patent Owner's Cancellation of Deposition | Aug 6, 2019 | PAPER | PATENT OWNER |
Patent Owner's Notice of Deposition of Mark Abramovitz, Ph.D | Jul 30, 2019 | PAPER | PATENT OWNER |
Declaration of Sylvia Hall-Ellis, Ph.D. | Jul 29, 2019 | EXHIBIT | PETITIONER |
Joint Stipulation to Modify Due Dates 1-3 | Jul 29, 2019 | PAPER | PATENT OWNER |
Decision Granting Petitioner's Motions for Pro Hac Vice Admission of David B. Bassett | Jul 23, 2019 | PAPER | BOARD |
Decision Granting Petitioner's Motions for Pro Hac Vice Admission of Shirley X. Li Cantin | Jul 23, 2019 | PAPER | BOARD |
Granting Petitioner's Motion to File Supplemental Information | Jul 22, 2019 | PAPER | BOARD |
Exhibit 3003 | Jul 22, 2019 | EXHIBIT | BOARD |
Petitioner's Updated Mandatory Notices | Jul 19, 2019 | PAPER | PETITIONER |
Exhibit 3002 | Jul 15, 2019 | EXHIBIT | BOARD |
ORDER Conduct of the Proceeding | Jul 15, 2019 | PAPER | BOARD |
Corrected Affidavit of Christopher Butler | Jul 15, 2019 | EXHIBIT | PETITIONER |
Petitioners Motion For Admission Pro Hac Vice Of David B. Bassett | Jul 3, 2019 | PAPER | PETITIONER |
Declaration Of David B. Bassett In Support Of Motion For Admission Pro Hac Vice | Jul 3, 2019 | EXHIBIT | PETITIONER |
Petitioners Motion For Admission Pro Hac Vice Of Shirley X. Li Cantin | Jul 3, 2019 | PAPER | PETITIONER |
Declaration Of Shirley X. Li Cantin In Support Of Motion For Admission Pro Hac Vice | Jul 3, 2019 | EXHIBIT | PETITIONER |
Patent Owner's Opposition to Petitioner's Motion to Submit Supplemental Information | Jul 1, 2019 | PAPER | PATENT OWNER |
PETITIONER'S MOTION TO SUBMIT SUPPLEMENTAL INFORMATION | Jun 24, 2019 | PAPER | PETITIONER |
EXPUNGED | Jun 24, 2019 | EXHIBIT | PETITIONER |
Declaration of Mark Abramovitz (June 3, 2019) | Jun 24, 2019 | EXHIBIT | PETITIONER |
Fixed on Expression, 4 Bio-IT World 22 (2005) | Jun 24, 2019 | EXHIBIT | PETITIONER |
Mark Abramovitz & Brian Leyland-Jones, A Systems Approach to
Clinical Oncology: Focus on Breast Cancer, 4 Proteome Sci. (2006) | Jun 24, 2019 | EXHIBIT | PETITIONER |
Illumina Seminar Series Notice, University of Florida, From Whole-
Genome to Whole-Solution, Disease Analysis Tools for the Next
Generation (Feb. 15, 2007) | Jun 24, 2019 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 24, 2019 | EXHIBIT | PETITIONER |
Seminar Notice, Sunnybrook Research Institute, Applying Genomic
and Proteomic Platforms Towards the Individualization of Treatment
for Breast Cancer Patients (Oct. 25, 2006) | Jun 24, 2019 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 24, 2019 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 24, 2019 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 24, 2019 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 24, 2019 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 24, 2019 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 24, 2019 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 24, 2019 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 24, 2019 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 24, 2019 | EXHIBIT | PETITIONER |
Jian-Bing Fan et al., Multiplexed RNA Profiling of Paraffin Samples -
Assay Tutorial Reproducible Gene Expression from Degraded RNAs
Using the DASL | Jun 24, 2019 | EXHIBIT | PETITIONER |
Order - Conduct of the Proceedings - 37 CFR 42.5 | Jun 18, 2019 | PAPER | BOARD |
Notice of Deposition of Paul T. Spellman, Ph.D | Jun 17, 2019 | PAPER | PATENT OWNER |
Patent Owner's Objections to Evidence | Jun 13, 2019 | PAPER | PATENT OWNER |
Trial Instituted Document | May 30, 2019 | PAPER | BOARD |
Scheduling Order | May 30, 2019 | PAPER | BOARD |
PANEL CHANGE ORDER
Conduct of the Proceedings
37 C.F.R. ¿¿ 42.5 | Apr 22, 2019 | PAPER | BOARD |
Patent Owner's Sur-Reply | Mar 29, 2019 | PAPER | PATENT OWNER |
Petitioner's Reply to Patent Owner's Preliminary Response | Mar 22, 2019 | PAPER | PETITIONER |
Conduct of the Proceeding
37 C.F.R. sec. 42.5 | Mar 15, 2019 | PAPER | BOARD |
Ex 3001 | Mar 14, 2019 | EXHIBIT | BOARD |
Declaration of Sandeep K. Reddy, submitted during prosecution of U.S. Patent App. 14/249,261 | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
U.S. Patent No. 8,880,350 | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
U.S. Patent No. 9,383,365 | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Patent Owner's Preliminary Response | Mar 6, 2019 | PAPER | PATENT OWNER |
Horstmann, et al. Risks and Benefits of Phase 1 Oncology Trials,
1991 through 2002 | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Wakelee, et al. Optimizing First Line Treatment Options for Patience with Advanced NSCLC | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Declaration of Michael Castro, submitted during prosecution of U.S. Patent App. 11/750,721 | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Benson, et al. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
National Comprehensive Cancer Network, Breast Cancer Clinical Practice Guidelines in Oncology | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Leyland Jones, Trastuzumab: Hopes and Realities, The Lancet Oncology | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
National Comprehensive Cancer Network, Colon Cancer Clinical Practice Guidelines in Oncology | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
U.S. Patent No. 9,292,660 | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Seena Magowitz Foundation, Dr. Daniel Von Hoff Wins ASCO Award | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Von Hoff, Pilot Study Using Molecular Profiling of Patients Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Doroshow, et al. Selecting Systemic Cancer Therapy One Patient at a Time | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Femara Prescribing Information | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Tamoxifen Prescribing Information | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
The Translational Genomics Research Institute, Dr. Daniel Von Hoff Presented with Top Genomics Award from Scripps | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Foundation Medicine, Inc., Foundation One Technical Information and Test Overview | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Foundation Medicine, Inc., Form 10-K, filed March 3, 2017 for the period ending December 31, 2016 | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
File Excerpt of U.S. Patent No. 8,880,350 | Mar 6, 2019 | EXHIBIT | PATENT OWNER |
Notice of Accord Filing Date | Dec 6, 2018 | PAPER | BOARD |
Patent Owner's Power of Attorney | Nov 19, 2018 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notices | Nov 19, 2018 | PAPER | PATENT OWNER |
Robert Langreth & Michael Waldholz, New Era of Personalized Medicine Targeting Drugs For Each Unique Genetic Profile, 4 The Oncologist 426 (1999) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Charles Sawyers, Targeted cancer therapy, 432 Nature 294, (2004) | Nov 5, 2018 | EXHIBIT | PETITIONER |
NHGRI Seeks Next Generation of Sequencing Technologies (Oct. 14, 2004) | Nov 5, 2018 | EXHIBIT | PETITIONER |
IressaTM (gefitinib) Prescribing Information (May 2, 2003) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Genomics and Personalized Medicine Act of 2006, S. 3822, 109th Cong | Nov 5, 2018 | EXHIBIT | PETITIONER |
Jackson B. Gibbs, Anticancer drug targets: growth factors and growth factor signaling, 105 J. Clinical Investigation 9 (2000) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Nida Iqbal & Naveed Iqbal, Imatinib: A Breakthrough of Targeted Therapy in Cancer, Chemotherapy Research & Practice 1 (2014) | Nov 5, 2018 | EXHIBIT | PETITIONER |
GleevecTM (imatinib mesylate) Prescribing Information (Jan. 22, 2002) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Herceptin® (trastuzumab) Prescribing Information (Sept. 1998) | Nov 5, 2018 | EXHIBIT | PETITIONER |
TarcevaTM (erlotinib) Prescribing Information (Nov. 18, 2004) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Henry Q. Xiong & James L. Abbruzzese, Epidermal growth factor receptor-targeted therapy for pancreatic cancer, 29 Seminars in Oncology 31 (2002) | Nov 5, 2018 | EXHIBIT | PETITIONER |
ErbituxTM (cetuximab) Prescribing Information (Feb. 12, 2004) | Nov 5, 2018 | EXHIBIT | PETITIONER |
ErbituxTM (cetuximab) Prescribing Information (Mar. 1, 2006) | Nov 5, 2018 | EXHIBIT | PETITIONER |
ClinicalTrials.gov, Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma, available at https://clinicaltrials.gov/ct2/show/NCT01515137 | Nov 5, 2018 | EXHIBIT | PETITIONER |
NCI Drug Dictionary, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cetuximab | Nov 5, 2018 | EXHIBIT | PETITIONER |
Thomas Jarvie, Next generation sequencing technologies, 2 Drug Discovery Today: Technologies 255 (2005) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Power of Attorney | Nov 5, 2018 | PAPER | PETITIONER |
Timothy R. Hughes et al., Functional Discovery via a Compendium of Expression Profiles, 102 Cell 109 (2000) | Nov 5, 2018 | EXHIBIT | PETITIONER |
X. Chen et al., TTD: Therapeutic Target Database, 30 Nucleic Acids Research 412 (2002) | Nov 5, 2018 | EXHIBIT | PETITIONER |
S. Forbes et al., COSMIC 2005, 94 British J. Cancer 318 (2006) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Justin Lamb et al., The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease, 313 Science 1929 (2006) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Oxford Dictionary of Biochemistry and Molecular Biology (Oxford University Press, 2d ed. 2006) | Nov 5, 2018 | EXHIBIT | PETITIONER |
HUGO Gene Nomenclature Committee Symbol Report: EGFR, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:3236 | Nov 5, 2018 | EXHIBIT | PETITIONER |
U.S. Provisional Patent Application No. 60/747,645 | Nov 5, 2018 | EXHIBIT | PETITIONER |
Xiaojun Zhao et al., Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis, 65 Cancer Research 5561 (2005) | Nov 5, 2018 | EXHIBIT | PETITIONER |
David Stipp, Gene Chip Breakthrough, Fortune Magazine, Mar. 31, 1997, at 56 | Nov 5, 2018 | EXHIBIT | PETITIONER |
Jian-Bing Fan et al., BeadArrayTM-based solutions for enabling the promise of pharmacogenomics, 39 BioTechniques 583 (2005) | Nov 5, 2018 | EXHIBIT | PETITIONER |
U.S. Patent No. 9,092,392 (the " '392 patent") | Nov 5, 2018 | EXHIBIT | PETITIONER |
Timothy K. Egan, Monitoring Patients Undergoing Cancer Therapy, 31 Lab. Med. 666 (2000) | Nov 5, 2018 | EXHIBIT | PETITIONER |
G. William Moore et al., A Prototype Internet Autopsy Database: 1625 Consecutive Fetal and Neonatal Autopsy Facesheets Spanning Twenty Years, 120 Archives Pathology Lab. Med. 782 (1996) | Nov 5, 2018 | EXHIBIT | PETITIONER |
HUGO Gene Nomenclature Committee Symbol Report: CASP8, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:1509 | Nov 5, 2018 | EXHIBIT | PETITIONER |
Phillip G. Febbo & Geoffrey S. Ginsburg, Personalized diagnostic and therapeutic strategies in oncology, 2 Personalized Medicine 97 (2005) | Nov 5, 2018 | EXHIBIT | PETITIONER |
HUGO Gene Nomenclature Committee Symbol Report: ERBB2, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:3430 | Nov 5, 2018 | EXHIBIT | PETITIONER |
Business Wire, Illumina Launches DASL Assay and Cancer Panel for Gene Expression Profiling of Paraffin-Embedded Samples (Jan. 13, 2005) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Marina Bibikova et al., Gene Expression Profiles in Formalin-Fixed, Paraffin-Embedded Tissues Obtained with a Novel Assay for Microarray Analysis, 50 Clinical Chemistry 2384 (2004) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Marina Bibikova et al., Quantitative Gene Expression Profiling in Formalin-Fixed, Paraffin-Embedded Tissues Using Universal Bead Arrays, 165 American J. Pathology 1799 (2004) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Jian-Bing Fan et al., A Versatile Assay for High-Throughput Gene Expression Profiling on Universal Array Matrices, 14 Genome Research 878 (2004) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Jeffrey S. Ross & Geoffrey S. Ginsburg, The Integration of Molecular Diagnostics with Therapeutics: Implications for Drug Development and Pathology Practice, 119 Am. J. Clinical Pathology 26 (2003) ("Ross") | Nov 5, 2018 | EXHIBIT | PETITIONER |
Masuko Katoh & Masaru Katoh, Bioinformatics for Cancer Management in the Post-Genome Era, 5 Technology in Cancer Research & Treatment 169 (2006) | Nov 5, 2018 | EXHIBIT | PETITIONER |
David S. Wishart et al, DrugBank: a comprehensive resource for in silico drug discovery and exploration, 34 Nucleic Acids Research D668 (2006) | Nov 5, 2018 | EXHIBIT | PETITIONER |
HUGO Gene Nomenclature Committee Symbol Report: ESR1, available at https://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:3467 | Nov 5, 2018 | EXHIBIT | PETITIONER |
NIH National Cancer Institute, How Imatinib Transformed Leukemia Treatment and Cancer Research, (updated Apr. 11, 2018) https://www.cancer.gov/research/progress/discovery/gleevec | Nov 5, 2018 | EXHIBIT | PETITIONER |
Claudia Dreifus, Researcher Behind the Drug Gleevec, N.Y. Times (Nov. 2, 2009), at D4 | Nov 5, 2018 | EXHIBIT | PETITIONER |
File History Excerpt | Nov 5, 2018 | EXHIBIT | PETITIONER |
PCT Publication No. WO 03/017038 (published Feb. 27, 2003) ("Lu") | Nov 5, 2018 | EXHIBIT | PETITIONER |
Dan L. Longo, Imatinib Changed Everything, 376 New England J. Med. 982 (2017) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Federico Cappuzzo et al., Clinical experience with gefitinib: An update, 58 Critical Reviews in Oncology/Hematology 31 (2006) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Complaint | Nov 5, 2018 | EXHIBIT | PETITIONER |
U.S. Patent No.9,372,193 (the"'193 patent") | Nov 5, 2018 | EXHIBIT | PETITIONER |
Illumina R Gene Expression Profiling, Technical Bulletin, RNA Profiling with the DASL R Assay (2005) ("Illumina") | Nov 5, 2018 | EXHIBIT | PETITIONER |
U.S. Patent Publication No. 2002/0150966 ("Muraca") | Nov 5, 2018 | EXHIBIT | PETITIONER |
Amy L. McDoniels-Silvers et al., Differential Expression of Critical Cellular Genes in Human Lung Adenocarcinomas and Squamous Cell Carcinomas in Comparison to Normal Lung Tissues, 4 Neoplasia 141 (2002) | Nov 5, 2018 | EXHIBIT | PETITIONER |
S. Scholl, Targeting HER2 in Other Tumor Types, 12 Annals Oncology S81 (2001) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Atul J. Butte et al., Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks, 97 PNAS 12182 (2000) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Daniel R. Rhodes et al., Oncomine: A Cancer Microarray Database and Integrated Data-Mining Platform, 6 Neoplasia 1, 1 (2004) | Nov 5, 2018 | EXHIBIT | PETITIONER |
H. Parkinson, ArrayExpress - a public repository for microarray gene expression data at the EBI, 33 Nucleic Acids Research D553 (2005) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Alexander Statnikov et al., GEMS: A System for Automated Cancer Diagnosis and Biomarker Discovery from Microarray Gene Expression Data, 74 Int'l J. Med. Informatics 491 (2005) | Nov 5, 2018 | EXHIBIT | PETITIONER |
James Moyer et al., Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase, 57 Cancer Research 4838 (1997) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Jane E. Staunton et al., Chemosensitivity prediction by transcriptional profiling, 98 PNAS 10787 (2001) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Thomas M. Daly et al., Precision Profiling and Components of Variability Analysis for Affymetrix Microarray Assays Run in a Clinical Context, 7 J. Molecular Diagnostics 404 (2005) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Daniel R. Rhodes et al., Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression, 25 PNAS 9309 (2004) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Daniel R. Rhodes et al., Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles, 9 Neoplasia 166 (2007) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Jeremy Gollub et al., The Stanford Microarray Database: data access and quality assessment tools, 31 Nucleic Acids Research 94 (2003) | Nov 5, 2018 | EXHIBIT | PETITIONER |
C.J. Zheng et al., TRMP: a database of therapeutically relevant multiple pathways, 20 Bioinformatics 2236 (2004) | Nov 5, 2018 | EXHIBIT | PETITIONER |
Fee Authorization | Nov 5, 2018 | PAPER | PETITIONER |
Butler Affidavit | Nov 5, 2018 | EXHIBIT | PETITIONER |
Declaration of Paul T. Spellman, Ph.D. | Nov 5, 2018 | EXHIBIT | PETITIONER |
Petition IPR2019-00170 | Nov 5, 2018 | PAPER | PETITIONER |